Albuterol inhalation increases FeNO level in steroid-naive asthmatics but not COPD patients with reversibility

Clinical Respiratory Journal

Volumn 11, Issue 3, 2017, Pages 328-336

  Zhao, Haijin ^a   Li, Rui ^a   Yanhua, L V ^a   Dong, Hangming ^a   Yao, Lihong ^a   Wu, Yue ^a   Xiao, Guanhua ^a   Cai, Shaoxi ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

airway calibers asthma COPD fractional exhaled nitric oxide positive bronchodilator test

Indexed keywords

CORTICOSTEROID; FRACTIONAL EXHALED NITRIC OXIDE; NITRIC OXIDE; SALBUTAMOL; STEROID; UNCLASSIFIED DRUG; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SPIROMETRY; SPUTUM ANALYSIS; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; EOSINOPHIL; EXHALATION; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; SMOKING; SPUTUM;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; DIAGNOSIS, DIFFERENTIAL; EOSINOPHILS; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SPIROMETRY; SPUTUM;

EID: 84936802772     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12340     Document Type: Article

References (35)

1. Ludviksdottir D, Diamant Z, Alving K, Bjermer L, Malinovschi A. Clinical aspects of using exhaled NO in asthma diagnosis and management. Clin Respir J. 2012;6: 193–207.
2. Donohue JF, Jain N. Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates. Respir Med. 2013;107: 943–52.
3. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184: 602–15.
4. Guan WJ, Shi X, Jiang CY, Xie YQ, Zhu Z, Gao Y, Zheng JP. Responsiveness to methacholine, but not leukotriene D4, correlates with fractional exhaled nitric oxide in asthma. Clin Respir J. 2014 Aug 8; doi: 10.1111/crj.12199.
5. de Gouw HW, Hendriks J, Woltman AM, Twiss IM, Sterk PJ. Exhaled nitric oxide (NO) is reduced shortly after bronchoconstriction to direct and indirect stimuli in asthma. Am J Resp Crit Care. 1998;158: 315–9.
6. Silkoff PE, Wakita S, Chatkin J, Ansarin K, Gutierrez C, Caramori M, McClean P, Slutsky AS, Zamel N, Chapman KR. Exhaled nitric oxide after beta2-agonist inhalation and spirometry in asthma. Am J Respir Crit Care Med. 1999;159: 940–4.
7. Garnier P, Fajac I, Dessanges JF, Dall'Ava-Santucci J, Lockhart A, Dinh-Xuan AT. Exhaled nitric oxide during acute changes of airways calibre in asthma. Eur Respir J. 1996;9: 1134–8.
8. Kharitonov SA, Sapienza MA, Barnes PJ, Chung KF. Prostaglandins E2 and F2alpha reduce exhaled nitric oxide in normal and asthmatic subjects irrespective of airway caliber changes. Am J Respir Crit Care Med. 1998;158: 1374–8.
9. Yates DH, Kharitonov SA, Barnes PJ. Effect of short-and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. Eur Respir J. 1997;10: 1483–8.
10. Colon-Semidey AJ, Marshik P, Crowley M, Katz R, Kelly HW. Correlation between reversibility of airway obstruction and exhaled nitric oxide levels in children with stable bronchial asthma. Pediatr Pulmonol. 2000;30: 385–92.
11. Silvestri M, Sabatini F, Sale R, Defilippi AC, Fregonese L, Battistini E, Biraghi MG, Rossi GA. Correlations between exhaled nitric oxide levels, blood eosinophilia, and airway obstruction reversibility in childhood asthma are detectable only in atopic individuals. Pediatr Pulm. 2003;35: 358–63.
12. Sitkauskiene B, Sakalauskas R, Malakauskas K, Lotvall J. Reversibility to a beta2-agonist in COPD: relationship to atopy and neutrophil activation. Respir Med. 2003;97: 591–8.
13. Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I, Saetta M, Ciaccia A, Fabbri LM. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162: 1773–7.
14. Kroegel C. Global Initiative for Asthma (GINA) guidelines: 15 years of application. Expert Rev Clin Immunol. 2009;5: 239–49.
15. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176: 532–55.
16. Paggiaro PL, Chanez P, Holz O, Ind PW, Djukanović R, Maestrelli P, Sterk PJ. Sputum induction. Eur Respir J Suppl. 2002;37: 3s–8s.
17. Gelb AF, George SC, Silkoff PE, Krishnan A, Fraser C, Taylor CF, Shinar CM, Maginot T. Central and peripheral airway/alveolar sites of exhaled nitric oxide in acute asthma. Thorax. 2010;65: 619–25.
18. Tadaki H, Mochizuki H, Muramastu R, Hagiwara S, Takami S, Mizuno T, Arakawa H. Effect of bronchoconstriction on exhaled nitric oxide levels in healthy and asthmatic children. Ann Allergy Asthma Immunol. 2009;102: 469–74.
19. Teague WG1, Tustison NJ, Altes TA. Ventilation heterogeneity in asthma. J Asthma. 2014;51(7): 677–84.
20. Newby C, Heaney LG, Menzies-Gow A, et al. Statistical cluster analysis of the British Thoracic Society Severe refractory Asthma Registry: clinical outcomes and phenotype stability. PLoS One. 2014;9: e102987.
21. Lim S, Jatakanon A, John M, Gilbey T, O'connor BJ, Chung KF, Barnes PJ. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med. 1999;159: 22–30.
22. Ten BA, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001;164: 744–8.
23. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174: 6–14.
24. Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010;138: 682–92.
25. Lacoste JY, Bousquet J, Chanez P, Van Vyve T, Simony-Lafontaine J, Lequeu N, Vic P, Enander I, Godard P, Michel FB. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 1993;92: 537–48.
26. Ghebre MA, Bafadhel M, Desai D, et al. Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014; pii: S0091-6749(14)00951-8.
27. Papaiwannou A, Zarogoulidis P, Porpodis K, et al. Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review. J Thorac Dis. 2014;6(Suppl. 1): S146–51.
28. Dummer JF, Taylor DR. Defining the role of exhaled nitric oxide measurements in COPD. Respirology. 2010;15: 385–6.
29. Rutgers SR, van der Mark TW, Coers W, Moshage H, Timens W, Kauffman HF, Koëter GH, Postma DS. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax. 1999;54: 576–80.
30. Strunk RC, Szefler SJ, Phillips BR, et al. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol. 2003;112: 883–92.
31. Silkoff PE, Martin D, Pak J, Westcott JY, Martin RJ. Exhaled nitric oxide correlated with induced sputum findings in COPD. Chest. 2001;119: 1049–55.
32. Lim S, Jatakanon A, Meah S, Oates T, Chung KF, Barnes PJ. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma. Thorax. 2000;55: 184–8.
33. Lim S, Tomita K, Caramori G, Jatakanon A, Oliver B, Keller A, Adcock I, Chung KF, Barnes PJ. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med. 2001;164: 273–6.
34. Bjermer L, Alving K, Diamant Z, et al. Current evidence and future research needs for FeNO measurement in respiratory diseases. Respir Med. 2014;108: 830–41.
35. Agrawal S, Townley RG. Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma. Expert Opin Biol Ther. 2014;14: 165–81.